SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer.
cancer progression
gastric cancer
notch signaling
spondin-2 (SPON2)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
29
04
2020
revised:
27
05
2020
accepted:
30
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Spondin-2 (SPON2) is involved in cancer progression and metastasis of many tumors; however, its role and underlying mechanism in gastric cancer are still obscure. In this study, we investigated the role of SPON2 and related signaling pathway in gastric cancer progression and metastasis. SPON2 expression levels were found to be upregulated in gastric cancer cell lines and patient tissues compared to normal gastric epithelial cells and normal controls. Furthermore, SPON2 silencing was observed to decrease cell proliferation and motility and reduce tumor growth in xenograft mice. Conversely, SPON2 overexpression was found to increase cell proliferation and motility. Subsequently, we focused on regulatory mechanism of SPON2 in gastric cancer. cDNA microarray and in vitro study showed that Notch signaling is significantly correlated to SPON2 expression. Therefore, we confirmed how Notch signaling pathway regulate SPON2 expression using Notch signaling-related transcription factor interaction and reporter gene assay. Additionally, activation of Notch signaling was observed to increase cell proliferation, migration, and invasion through SPON2 expression. Our study demonstrated that Notch signaling-mediated SPON2 upregulation is associated with aggressive progression of gastric cancer. In conclusion, we suggest upregulated SPON2 via Notch signaling as a potential target gene to inhibit gastric cancer progression.
Identifiants
pubmed: 32492954
pii: cancers12061439
doi: 10.3390/cancers12061439
pmc: PMC7352369
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Foundation (NRF) of Korea grants
ID : NRF-2017R1C1B2005265, NRF-2017R1A2B2006238, NRF-2019R1A2C2089237, NRF-2015M3A9B6073835, NRF-2016K1A3A1A47921595
Organisme : Korea Brain Research Institute funded by Ministry of Science and ICT
ID : BR-03-02
Références
Oncotarget. 2017 Apr 27;8(31):51963-51969
pubmed: 28881703
Oncotarget. 2016 Aug 2;7(31):49322-49333
pubmed: 27384994
Clin Microbiol Rev. 2010 Oct;23(4):713-39
pubmed: 20930071
Bull Cancer. 2014 Oct 8;:
pubmed: 25296411
PLoS One. 2012;7(5):e37225
pubmed: 22615945
World J Gastroenterol. 2014 Apr 28;20(16):4483-90
pubmed: 24782601
Surg Today. 2017 Nov;47(11):1295-1302
pubmed: 28251375
Oncotarget. 2015 Jun 20;6(17):15095-110
pubmed: 25945835
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Cancer Res. 2005 Sep 15;65(18):8397-405
pubmed: 16166318
Oncogene. 2018 Feb 1;37(5):601-615
pubmed: 28991232
Oncotarget. 2017 May 11;8(32):53839-53853
pubmed: 28881855
PLoS Biol. 2008 Oct 21;6(10):e257
pubmed: 18942891
Gastroenterology. 2013 Jul;145(1):166-175.e8
pubmed: 23541909
Cancer Res. 2000 Jul 1;60(13):3333-7
pubmed: 10910033
Crit Rev Oncol Hematol. 2009 Aug;71(2):127-64
pubmed: 19230702
Clin Cancer Res. 2018 Dec 15;24(24):6136-6141
pubmed: 30104200
Cancer Res. 2018 May 1;78(9):2305-2317
pubmed: 29440144
J Cell Mol Med. 2020 Jan;24(1):98-113
pubmed: 31691494
Mol Cancer. 2016 Dec 9;15(1):80
pubmed: 27938406
Pathol Res Pract. 2019 Feb;215(2):286-291
pubmed: 30527359
World J Gastroenterol. 2015 Oct 21;21(39):10948-55
pubmed: 26494953
EMBO J. 2009 Feb 4;28(3):286-97
pubmed: 19153605
Oncogene. 2016 Nov 17;35(46):5942-5952
pubmed: 26686083
Cancer Lett. 2010 Sep 28;295(2):144-53
pubmed: 20488613
World J Gastrointest Oncol. 2015 Dec 15;7(12):401-10
pubmed: 26690491
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancer Lett. 2015 Dec 1;369(1):20-7
pubmed: 26341688
Science. 1999 Apr 30;284(5415):770-6
pubmed: 10221902
World J Exp Med. 2015 May 20;5(2):84-102
pubmed: 25992323
Oncotarget. 2017 Feb 7;8(6):10416-10424
pubmed: 28060752
Oncotarget. 2014 May 30;5(10):3386-98
pubmed: 24930499
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Int Med Res. 2019 Feb;47(2):569-579
pubmed: 30318967
Expert Rev Gastroenterol Hepatol. 2015;9(12):1549-60
pubmed: 26414453
J Cell Sci. 2013 May 15;126(Pt 10):2135-40
pubmed: 23729744
EMBO Mol Med. 2017 Jul;9(7):950-966
pubmed: 28539479
Gastroenterology. 2019 Mar;156(4):1140-1155.e4
pubmed: 30508510
Cancer Biol Ther. 2002 Sep-Oct;1(5):466-76
pubmed: 12496471
Cold Spring Harb Perspect Biol. 2012 Apr 01;4(4):a007989
pubmed: 22474007
J Cancer Res Ther. 2018 Dec;14(Supplement):S1230-S1232
pubmed: 30539878